Trials / Completed
CompletedNCT01001806
A Comparison of Peak Aqueous Penetration of Acuvail (Ketorolac 0.45%), Xibrom (Bromfenac 0.09%), and Nevanac (Nepafenac 0.1%)in Patients Undergoing Phacoemulsification
A Comparison of Peak Aqueous Penetration of Acuvail, Xibrom, and Nevanac in Patients Undergoing Phacoemulsification
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 126 (actual)
- Sponsor
- Frank A. Bucci, Jr., M.D. · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
Approximately 126 subjects scheduled to undergo cataract surgery by phacoemulsification, will be randomized in an even allocation (1:1:1) to either Acuvail, Xibrom, or Nevanac. Subjects will be instructed to begin dosing the study medication in the operative eye the day before surgery and continue dosing on the day of surgery. Beginning one hour before surgery, 1 drop of study medication will be instilled by operating room staff approximately every 15 minutes for a total of 3 doses. At the designated time a paracentesis will be performed at the start of the cataract procedure and at least 0.15 cc of aqueous humor will be collected. The sample will be immediately stored on dry ice and shipped to a laboratory for analysis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ketorolac Tromethamine 0.45% | One drop BID the day before surgery and then 3 doses the day of surgery prior to surgery |
| DRUG | bromfenac 0.09% | One day pre operative 1 drop BID then 3 doses pre op day of surgery |
| DRUG | nepafenac 0.1% | One drop BID, 1 day pre operative and then 3 doses the day of surgery |
Timeline
- Start date
- 2009-10-01
- Primary completion
- 2009-12-01
- Completion
- 2010-01-01
- First posted
- 2009-10-27
- Last updated
- 2011-10-03
- Results posted
- 2011-08-26
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01001806. Inclusion in this directory is not an endorsement.